menu
    • menu

    Company profile for SkylineDx

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At SkylineDx, we live to make a difference. It is our mission to improve a patient’s quality of life by enabling them to benefit from personal insights at the genomic level of their disease. That means we are continuously innovating the world of gene signature-based diagnostic testing.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SkylineDxNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    SkylineDx BV Brainpark II - Building XI Lichtenauerlaan 40 3062ME Rotterdam
    Telephone
    Telephone
    +31 (0)10 72 00 310
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.skylinedx.com/home
    Linkedin
    Linkedin
    https://www.linkedin.com/company/skylinedx-bv
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/skylinedx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merlin CP-GEP Predicts Sentinel-Node Metastasis in Early Melanoma
    Merlin CP-GEP Predicts Sentinel-Node Metastasis in Early Melanoma

    25 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/merlin-cp-gep-demonstrates-superior-predictive-accuracy-for-sentinel-lymph-node-metastasis-in-early-stage-melanoma-302723338.html

    PR NEWSWIRE
    25 Mar 2026
    Share Share
    SkylineDx Launches SLNB Initiative Targeting Early-Stage Melanoma
    SkylineDx Launches SLNB Initiative Targeting Early-Stage Melanoma

    05 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/skylinedx-launches-a-guideline-informed-risk-assessment-initiative-to-support-slnb-decision-making-in-early-stage-melanoma-302705274.html

    PR NEWSWIRE
    05 Mar 2026
    Share Share
    Merlin CP-GEP Added to NCCN Melanoma Guide
    Merlin CP-GEP Added to NCCN Melanoma Guide

    19 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/merlin-cp-gep-becomes-the-first-and-only-gene-expression-profile-gep-test-recommended-by-nccn-cutaneous-melanoma-guidelines-to-assess-metastatic-risk-302692470.html

    PR NEWSWIRE
    19 Feb 2026
    Share Share
    SkylineDx: Merlin CP-GEP Leads in Melanoma Risk Assessment
    SkylineDx: Merlin CP-GEP Leads in Melanoma Risk Assessment

    18 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/new-data-from-skylinedx-demonstrates-merlin-cp-gep-tests-superior-melanoma-risk-stratification-302644914.html

    PR NEWSWIRE
    18 Dec 2025
    Share Share
    Skylinedx Validate Merlin CP-GEP Test In Melanoma In JAMA Surgery
    Skylinedx Validate Merlin CP-GEP Test In Melanoma In JAMA Surgery

    22 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/skylinedx-publishes-landmark-merlin001-trial-in-jama-surgery-validating-the-predictive-power-of-the-merlin-cp-gep-test-in-melanoma-302590009.html

    PR NEWSWIRE
    22 Oct 2025
    Share Share
    SkylineDx's Merlin Melanoma Assay cuts SLNB by over 40%
    SkylineDx's Merlin Melanoma Assay cuts SLNB by over 40%

    22 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/skylinedxs-merlin-melanoma-assay-shows-its-ability-to-reduce-slnb-by-over-40-in-a-danish-multicenter-validation-study-302509635.html

    PR NEWSWIRE
    22 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search